Early Phase 1
Completed N=138
Drugs Brain and Behavior (DDP)
Stimulant Use
Source: ClinicalTrials.gov NCT04642820 ↗
Enrolled (actual)
138
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8; 28.6; 76.3 score on a scale — p=.05
Summary
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). |
19.2; 57.8; 28.6; 76.3; 25.2; 26.8 | .05 |
Eligibility Criteria
Inclusion Criteria
- BMI between 19 and 26
- Right Handed
- Less than 4 alcohol or caffeinated beverages a day.
Exclusion Criteria
- High blood pressure
- Any medical condition requiring regular medication
- Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
- Individuals with a history of dependence on stimulant drugs
- Women who are pregnant or trying to become pregnant.
Data sourced from ClinicalTrials.gov (NCT04642820). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.